Terms and Conditions
PLEASE READ AND REVIEW THE FOLLOWING TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE OPERATED BY VALIDUS PHARMACEUTICALS LLC. ("VALIDUS"). By using this website, you agree to these terms and conditions. If you do not agree, please exit this website.
This website and its contents is designed to comply with U.S. laws and regulations only.
This website contains material about Validus and certain of its products. Certain sections of this website are intended for particular audiences, including customers, members of the health care community and the general public.
By using this site you acknowledge that Validus is providing the material for informational purposes only and that neither Validus nor their agents, affiliates, partners, or licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials. Only your doctor or other health care professional can determine if a product described in this website is appropriate for you.
PLEASE CONSULT WITH A DOCTOR BEFORE USING ANY PRODUCT DISCUSSED IN THIS WEBSITE OR IN CONNECTION WITH ANY TREATMENT OPTIONS THAT MAY BE AVAILABLE TO YOU.
As a user of this website you are liable for the information you provide to us including, but not limited to, your state license number and your professional representation.
Any information provided by a user of this website including questions, comments, suggestions, or the like shall be deemed non-confidential and Validus shall have no obligation of any kind with respect to such information. Validus is entitled to use any such information for any purpose whatsoever.
By using this website, you accept the information, products, and services provided herein "as is". Validus makes no express or implied warranty regarding the accuracy, content, completeness, reliability, operability, or legality of information contained within this website, including, without limitation, the warranties of merchantability, fitness for a particular purpose, and non-infringement of proprietary rights.
Validus reserves the right to suspend or terminate your access to this website if you violate these terms and conditions. If your violation causes harm to others, you agree to indemnify and hold harmless from and against any and all loss, damage or expense. If any dispute arises between us regarding these terms and conditions or your use of this website, it shall be resolved through good faith negotiations between the parties and if unsuccessful, by binding arbitration governed by the rules of the American Arbitration Association. The arbitration award shall be binding and it may be enforced in any court of competent jurisdiction. Each party shall pay for all attorneys fees incurred as a result of any such arbitration and shall share equally in the costs of the arbitration. The venue for any arbitration shall be New Jersey. In no event shall Validus or its agents, affiliates, partners, or licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our websites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.
Please click here to review the Equetro® references.
WARNING
Important Safety Information about Equetro® (carbamazepine) Extended-Release Capsules
Warning Serious Dermatologic Reactions and HLA-B*1502 Allele
Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported during treatment with carbamazepine. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly caucasian populations, but the risk in some Asian countries is estimated to be about 10 times higher. Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. HLA-B*1502 is found almost exclusively in patients with ancestry across broad areas of Asia. Patients with ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 prior to initiating treatment with Equetro® (carbamazepine) Extended-Release Capsules. Patients testing positive for the allele should not be treated with Equetro® (carbamazepine) Extended-Release Capsules unless the benefit clearly outweighs the risk (see warnings and precautions, laboratory tests).
Aplastic Anemia and Agranulocytosis
Aplastic Anemia and Agranulocytosis have been reported in association with the use of carbamazepine. Data from a population based case-control study demonstrate that the risk of developing these reactions is 5–8 times greater than in the general population. However, the overall risk of these reactions in the untreated general population is low, approximately six patients per one million population per year for Agranulocytosis and two patients per one million population per year for Aplastic Anemia.
Although reports of transient or persistent decreased platelet or white blood cell counts are not uncommon in association with the use of carbamazepine, data are not available to estimate accurately their incidence or outcome. However, the vast majority of the cases of leukopenia have not progressed to the more serious conditions of Aplastic Anemia or Agranulocytosis.
Because of the very low incidence of Agranulocytosis and Aplastic Anemia, the vast majority of minor hematologic changes observed in monitoring of patients on carbamazepine are unlikely to signal the occurrence of either abnormality. Nonetheless, complete pretreatment hematological testing should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops.
Anti-epileptic drugs (AEDs), including Equetro®, may increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence of worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Please see FULL PRESCRIBING INFORMATION including contraindications, warnings and precautions, and boxed warning for additional safety information on Equetro® (carbamazepine) Extended-Release Capsules.
Please see Medication Guide for additional information.
